Development of Early Detection Signs for Gastrointestinal Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/11/2017 |
| Start Date: | September 2003 |
| End Date: | February 2018 |
Investigation of the Immune Response to Gastrointestinal Tumors and Development of Novel Biomarkers for the Presence of Gastrointestinal Cancer
Therapies involving the immune system have already shown great promise in early clinical
trials for the treatment of renal cell carcinoma and melanoma. One of the great challenges
now facing this field is to extend these findings to other cancers. Little is currently
understood about the nature of the immune response to more common gastrointestinal cancers.
The first goal of this proposal is to collect blood and tissue samples from patients with
early or late stage gastrointestinal cancers. These samples will be evaluated to better
understand the immune response to these two cancers. The second goal of this proposal is to
evaluate the specimens of these patients for changes and genetic markers that correlate with
the presence of cancer. The information gathered from these studies will directly enhance our
ability to design, conduct and monitor novel immunotherapeutic protocols for the treatment of
patients with gastrointestinal cancer.
trials for the treatment of renal cell carcinoma and melanoma. One of the great challenges
now facing this field is to extend these findings to other cancers. Little is currently
understood about the nature of the immune response to more common gastrointestinal cancers.
The first goal of this proposal is to collect blood and tissue samples from patients with
early or late stage gastrointestinal cancers. These samples will be evaluated to better
understand the immune response to these two cancers. The second goal of this proposal is to
evaluate the specimens of these patients for changes and genetic markers that correlate with
the presence of cancer. The information gathered from these studies will directly enhance our
ability to design, conduct and monitor novel immunotherapeutic protocols for the treatment of
patients with gastrointestinal cancer.
The first goal of this proposal is to collect cells from the peripheral blood, tumor draining
lymph nodes and tumor infiltrating lymphocytes in patients with early or late stage
gastrointestinal cancers. These samples will be evaluated in a variety of immunological
assays to better understand the immune response to these two cancers. The second goal of this
proposal is to evaluate using novel proteomic, cellomic, and genomic techniques the serum and
peripheral blood lymphocytes of these patients for protein, cellular changes and genetic
markers that correlate with the presence of cancer. The information gathered from these
studies will directly enhance our ability to design, conduct and monitor novel
immunotherapeutic protocols for the treatment of patients with gastrointestinal cancer.
lymph nodes and tumor infiltrating lymphocytes in patients with early or late stage
gastrointestinal cancers. These samples will be evaluated in a variety of immunological
assays to better understand the immune response to these two cancers. The second goal of this
proposal is to evaluate using novel proteomic, cellomic, and genomic techniques the serum and
peripheral blood lymphocytes of these patients for protein, cellular changes and genetic
markers that correlate with the presence of cancer. The information gathered from these
studies will directly enhance our ability to design, conduct and monitor novel
immunotherapeutic protocols for the treatment of patients with gastrointestinal cancer.
Inclusion Criteria:
- histologically confirmed GI malignancy
- suspected GI malignancy
- high risk individual as assessed by their physician
We found this trial at
1
site
5150 Centre Ave
Pittsburgh, Pennsylvania 15232
Pittsburgh, Pennsylvania 15232
(412) 647-2811
Phone: 412-692-2852
University of Pittsburgh Cancer Institute Founded in 1985, the University of Pittsburgh Cancer Institute (UPCI)...
Click here to add this to my saved trials
